BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference
22 déc. 2022 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Participate in the Jefferies London Healthcare Conference
08 nov. 2022 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Announces $65 Million Underwritten Offering of its Common Stock
04 nov. 2022 09h08 HE
|
BioAtla, Inc.
SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
03 nov. 2022 16h01 HE
|
BioAtla, Inc.
Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in NSCLC continue to show antitumor activity with additional patients enrolledBA3011 Undifferentiated Pleomorphic Sarcoma (UPS) enrollment in...
BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022
27 oct. 2022 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress
09 août 2022 16h05 HE
|
BioAtla, Inc.
Mecbotamab vedotin (BA3011) Phase 2 preliminary observations in Non-Small Cell Lung Carcinoma (NSCLC) supports advancing to the registrational stage of the study; anticipate full interim data set in...
BioAtla to Participate in the 2022 BTIG Biotechnology Conference
03 août 2022 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022
02 août 2022 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Participate in 2022 Jefferies Global Healthcare Conference
01 juin 2022 16h05 HE
|
BioAtla, Inc.
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress
04 mai 2022 16h01 HE
|
BioAtla, Inc.
– Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim data support advancing with UPS and osteosarcoma – – Mecbotamab vedotin (BA3011) Phase 2 interim analysis in NSCLC anticipated in first...